CERo Therapeutics Holdings
South San Francisco, California, United States · Biotechnology, Health Care, Other
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy, redirecting patient-derived T cells to eliminate tumors by employing pha
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 16
- Industries
- Biotechnology, Health Care, Other
- Status
- Public (CERO)
- Website
- cero.bio
- Company page
Recent activity at CERo Therapeutics Holdings
- : SEC 8-K (1.01): On August 27, 2026, Cero Therapeutics Holdings, Inc. completed a secured financing transaction with SRX Global Inc., where the Company issued a Consolidated Senior Secured Promissory Note with an original issue date of the same date. This transaction consolidates certain outstanding convertible grid promissory notes that were previously issued to SRX. The financing is significant as it helps in managing the company's debt obligations and potentially supports its future operations and growth strategies. No specific financial amounts were detailed regarding the Note in the report.
- : SEC 8-K (1.01): On October 14, 2025, Cero Therapeutics Holdings, Inc. entered into a Securities Purchase Agreement with certain accredited investors (referred to as PIPE Investors) to sell up to 9,750 shares of its Series E convertible preferred stock at a total price of up to $7 million. This agreement represents a significant capital raise for the company, which will likely be used to support its ongoing operations and growth initiatives. The agreement is structured to allow for one or more closings, depending on market and operational conditions, enhancing the financial flexibility for Cero Therapeutics. This move reflects the company’s strategic efforts to bolster its equity base amidst its operational needs.
- : CERo Therapeutics Holdings
Employee benefit plans
CERo Therapeutics Holdings files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About CERo Therapeutics Holdings: questions and answers
What does CERo Therapeutics Holdings do?
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy, redirecting patient-derived T cells to eliminate tumors by employing pha
Where is CERo Therapeutics Holdings headquartered?
CERo Therapeutics Holdings is headquartered in South San Francisco, California, United States.
How many employees does CERo Therapeutics Holdings have?
CERo Therapeutics Holdings has about 16 employees.
What is the latest news on CERo Therapeutics Holdings?
On Aug 27, 2026, SEC 8-K (1.01): On August 27, 2026, Cero Therapeutics Holdings, Inc. completed a secured financing transaction with SRX Global Inc., where the Company issued a Consolidated Senior Secured Promissory Note with an original issue date of the same date. This transaction consolidates certain outstanding
Is CERo Therapeutics Holdings a public company?
Yes. CERo Therapeutics Holdings is publicly traded under the ticker CERO.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy